Accelerating Your COVID-19 Vaccine Development

Accelerate patient recruitment in a competitive landscape

Increase your chances to connect with patients and expedite your recruitment.

• Labcorp Patient Direct enables access to direct-to-patient recruitment with U.S.-based patients who have expressed interest in participating in clinical trials* and meet initial pre-screen criteria
• COVID-19 Clinical Trial Connect is designed to accelerate patient recruitment for COVID-19 trials by collecting interested U.S.-based patients to participate in COVID-related clinical trials in their area

Incorporate integral testing into your studies 

Reliably detect an immune response to the SARS-CoV-2 virus in your vaccine studies. 

• Leverage decades of experience to provide functional, cell-based infectivity assays that assess neutralizing antibody activity, along with state-of-the-art serological assays for the detection and quantitation of SARS-CoV-2 antibody isotype responses (IgG, IgA, IgM)
• Characterize your vaccine candidates and determine if they elicit a neutralizing antibody response 

You can access a breadth of testing capabilities to screen candidates as part of your vaccine clinical trials or evaluate endpoints of your vaccine trial.

• PBMC isolation for downstream testing to assess response to vaccine candidates
• Genomic testing using different specimen types for viral load testing
• Extensive flow cytometry and immunology offerings
• Comprehensive safety testing menu of more than 700 assays